Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Inhibition of Parp1 by BMN673 effectively sensitizes cells to radiotherapy by upsetting the balance of repair pathways processing DNA double-strand breaks.

Soni A, Li F, Wang Y, Grabos M, Krieger LM, Chaudhary S, Hasan MSM, Ahmed MM, Coleman CN, Teicher BA, Piekarz RL, Wang D, Iliakis GE.

Mol Cancer Ther. 2018 Jul 3. pii: molcanther.0836.2017. doi: 10.1158/1535-7163.MCT-17-0836. [Epub ahead of print]

PMID:
29970481
2.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
3.

Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.

Kim J, Singh H, Ayalew K, Borror K, Campbell M, Johnson LL, Karesh A, Khin NA, Less JR, Menikoff J, Minasian L, Mitchell SA, Papadopoulos EJ, Piekarz RL, Prohaska KA, Thompson S, Sridhara R, Pazdur R, Kluetz PG.

Clin Cancer Res. 2018 Apr 15;24(8):1780-1784. doi: 10.1158/1078-0432.CCR-17-2555. Epub 2017 Dec 13.

PMID:
29237718
4.

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E.

Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.

5.

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.

6.

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.

Bates SE, Robey RW, Piekarz RL.

Clin Cancer Res. 2015 May 15;21(10):2195-7. doi: 10.1158/1078-0432.CCR-14-2555.

7.

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.

Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL.

Br J Haematol. 2015 Jul;170(1):96-109. doi: 10.1111/bjh.13400. Epub 2015 Apr 19.

8.

Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL.

Clin Cancer Res. 2013 Aug 15;19(16):4499-507. doi: 10.1158/1078-0432.CCR-13-0095. Epub 2013 Jun 11.

9.

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.

Clin Cancer Res. 2013 Jun 1;19(11):3095-104. doi: 10.1158/1078-0432.CCR-13-0109. Epub 2013 Apr 15.

10.

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.

Blood. 2013 May 16;121(20):4115-25. doi: 10.1182/blood-2012-08-449140. Epub 2013 Mar 26.

11.

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM.

Epigenomics. 2012 Oct;4(5):571-89. doi: 10.2217/epi.12.52.

PMID:
23130838
12.

Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S.

Clin J Oncol Nurs. 2012 Apr;16(2):195-204. doi: 10.1188/12.CJON.195-204.

PMID:
22459529
13.

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.

Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25.

14.

New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE.

Clin Cancer Res. 2010 Dec 1;16(23):5608-17. doi: 10.1158/1078-0432.CCR-09-1995. Review.

15.

Impact of ABCB1 allelic variants on QTc interval prolongation.

Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.

Clin Cancer Res. 2011 Feb 15;17(4):937-46. doi: 10.1158/1078-0432.CCR-10-0925. Epub 2010 Nov 24.

16.

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.

Clin Cancer Res. 2011 Feb 1;17(3):569-80. doi: 10.1158/1078-0432.CCR-10-1725. Epub 2010 Nov 16.

17.

Clinical Toxicities of Histone Deacetylase Inhibitors.

Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL.

Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. Review.

18.

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL.

Br J Haematol. 2010 Jan;148(2):256-67. doi: 10.1111/j.1365-2141.2009.07954.x. Epub 2009 Oct 28.

19.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.

J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13.

20.

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE.

Haematologica. 2009 Nov;94(11):1618-22. doi: 10.3324/haematol.2009.008607. Epub 2009 Jul 16.

21.

Epigenetic modifiers: basic understanding and clinical development.

Piekarz RL, Bates SE.

Clin Cancer Res. 2009 Jun 15;15(12):3918-26. doi: 10.1158/1078-0432.CCR-08-2788. Epub 2009 Jun 9.

22.

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.

Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215.

23.

Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

Bates SE, Piekarz RL.

Cancer J. 2007 Mar-Apr;13(2):80-3. No abstract available.

PMID:
17476134
24.
25.

Challenges of evaluating the cardiac effects of anticancer agents.

Bates SE, Rosing DR, Fojo T, Piekarz RL.

Clin Cancer Res. 2006 Jul 1;12(13):3871-4. Review. No abstract available.

26.

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE.

Clin Cancer Res. 2006 Jun 15;12(12):3762-73.

27.
28.

Effect of a histone deacetylase inhibitor on human cardiac mass.

Shizukuda Y, Piekarz RL, Bates SE, Sachdev V, Finkel T, Rosing DR.

Cardiovasc Drugs Ther. 2005 Jan;19(1):89-90. No abstract available.

PMID:
15883760
29.

Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

Hwang K, Piekarz RL, Bates SE, Figg WD, Sparreboom A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):81-6.

PMID:
15282096
30.

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE.

Blood. 2004 Jun 15;103(12):4636-43. Epub 2004 Mar 2.

31.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

32.

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE.

Blood. 2001 Nov 1;98(9):2865-8.

33.

Safety-modified episomal vectors for human gene therapy.

Cooper MJ, Lippa M, Payne JM, Hatzivassiliou G, Reifenberg E, Fayazi B, Perales JC, Morrison LJ, Templeton D, Piekarz RL, Tan J.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6450-5.

34.

Progesterone regulates the murine multidrug resistance mdr1b gene.

Piekarz RL, Cohen D, Horwitz SB.

J Biol Chem. 1993 Apr 15;268(11):7613-6.

35.

Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdr1b gene.

Yu L, Cohen D, Piekarz RL, Horwitz SB.

J Biol Chem. 1993 Apr 5;268(10):7520-6.

36.

Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells.

Kirschner LS, Greenberger LM, Hsu SI, Yang CP, Cohen D, Piekarz RL, Castillo G, Han EK, Yu LJ, Horwitz SB.

Biochem Pharmacol. 1992 Jan 9;43(1):77-87.

PMID:
1346495
37.

Structural and functional analysis of the mouse mdr1b gene promoter.

Cohen D, Piekarz RL, Hsu SI, DePinho RA, Carrasco N, Horwitz SB.

J Biol Chem. 1991 Feb 5;266(4):2239-44.

Supplemental Content

Loading ...
Support Center